Tuoyi
(Toripalimab)Phase 3Monoclonal antibody
Toripalimab is a cancer immunotherapy drug that helps the body's immune system fight certain types of cancer by blocking a protein that cancer cells use to hide from the immune system.[1] Tuoyi is currently being investigated across 70 indications[3], with its most advanced program in Phase 3.[1]
Tuoyi is one of 1144 small molecule programs targeting Tracheal Squamous Cell Carcinoma. It is currently in Phase 3.
70
Indications
300
Total Trials
117
Active Trials
1,143
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 70 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tuoyi
CCoherus Oncology, Inc.
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
DATROWAY
Daiichi SankyoPreclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nasopharyngeal Carcinoma12 trials
Show 9 more trials
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
Recruiting·—·Phase 3·NCT04376866·204 enrolled
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Not yet recruiting·—·Phase 2·NCT07136519·30 enrolled
Toripalimab11 trials
Show 8 more trials
Toripalimab Combined With SBRT for NSCLC
Active, not recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06293690·40 enrolled
Breast Cancer10 trials
Show 7 more trials
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Unknown status·—·Phase 2·NCT04389073·138 enrolled
Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06964906·140 enrolled
Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07410234·110 enrolled
Hepatocellular Carcinoma9 trials
Show 6 more trials
Small Cell Lung Cancer8 trials
Show 5 more trials
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Not yet recruiting·—·Phase 2·NCT07376499·31 enrolled
82 more indications
Patients With Advanced Solid Tumors7 trials
Show 4 more trials
Esophageal Squamous Cell Carcinoma7 trials
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07272291·48 enrolled
Show 4 more trials
Melanoma7 trials
Show 4 more trials
Advanced Solid Tumors7 trials
Show 4 more trials
Head and Neck Squamous Cell Carcinoma5 trials
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06208826·268 enrolled
Show 2 more trials
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 3·NCT06647563·355 enrolled
Urothelial Carcinoma4 trials
Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma
Unknown status·—·Phase 2·NCT04099589·64 enrolled
Locally Advanced4 trials
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT07246330·340 enrolled
Renal Cell Carcinoma4 trials
Show 1 more trial
Esophageal Cancer4 trials
Chemotherapy4 trials
Lymphoma3 trials
Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma
Active, not recruiting·—·Phase 2·NCT06492629·43 enrolled
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
Unknown status·—·Phase 2·NCT04338282·20 enrolled
Colorectal Cancer3 trials
PD-1antibody3 trials
High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04126460·41 enrolled
PD-1 Antibody Improve Mixed Chimerism
Unknown status·—·N/A·NCT04944511·20 enrolled
PD-1 Antibody for Reactive EBV After BMT
Unknown status·—·Phase 1·NCT04690036·20 enrolled
Triple-Negative Breast Cancer3 trials
Biliary Tract Cancer3 trials
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06717464·110 enrolled
Non-Small Cell Lung Cancer3 trials
Cervical Cancer3 trials
Lung Cancer2 trials
Immunotherapy2 trials
Adenocarcinoma2 trials
Gastric Cancer2 trials
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04354662·35 enrolled
Gastroesophageal Junction Adenocarcinoma2 trials
Patients With Solid Tumors2 trials
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
Recruiting·—·Phase 1/2·NCT06612632·100 enrolled
Advanced or Metastatic Solid Tumors2 trials
Metastatic Colorectal Cancer2 trials
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT04819516·10 enrolled
Oral Squamous Cell Carcinoma2 trials
Pancreatic Cancer2 trials
Advanced NSCLC2 trials
Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT04193098·10 enrolled
Induction Chemotherapy1 trial
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
Active, not recruiting·—·Phase 2·NCT05888402·50 enrolled
Prospective1 trial
Locally-advanced Rectal Cancer1 trial
Advanced Solid Tumours1 trial
Cervical Adenocarcinoma1 trial
Non-Small-Cell Lung1 trial
Gastric/Gastroesophageal Junction Cancer1 trial
Advanced Malignant Tumors1 trial
Rectal Adenocarcinoma1 trial
Locally Advanced Colon Cancer1 trial
Metastatic Urothelial Cancer1 trial
Tracheal Squamous Cell Carcinoma1 trial
Bladder Cancer1 trial
Neoadjuvant Therapy1 trial
Gemcitabine1 trial
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07189793·106 enrolled
Advanced Malignant Solid Tumors1 trial
Esophageal Carcinoma1 trial
Anti-PD-1 Antibody1 trial
Cholangiocarcinoma1 trial
Stereotactic Body Radiotherapy1 trial
Small Cell Carcinoma1 trial
Concurrent Chemoradiotherapy1 trial
Metastasis1 trial
Liposarcoma1 trial
Recurrent or Metastatic1 trial
Pancreatic Ductal Adenocarcinoma1 trial
HER2-Negative1 trial
Pathological Response1 trial
Urothelial Cancer1 trial
Maintenance Therapy1 trial
Head and Neck Squamous Cell Cancer1 trial
Advanced Solid Malignancies1 trial
Efficacy and Safety1 trial
Ovarian Cancer1 trial
Adjuvant Therapy1 trial
Metastatic1 trial
First-line Treatment1 trial
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07244874·41 enrolled
Mucosal Melanoma1 trial
Thyroid Cancer1 trial
Renal insufficiency1 trial
NSCLC1 trial
Papilloma1 trial
Neoadjuvant Chemotherapy1 trial
Malignant Pleural Mesothelioma1 trial
Other Solid Tumors1 trial
Brain Metastases1 trial
Cutaneous Melanoma1 trial
Locally Advanced Unresectable or Metastatic Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Toripalimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Programmed Cell Death Protein 1 Antagonist[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- CCoherus Oncology, Inc.